The efficancy of calcium release-activated calcium channel inhitibors in the treatment of rheumatoid arthritis
Project/Area Number |
15K19575
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Collagenous pathology/Allergology
|
Research Institution | Ehime University |
Principal Investigator |
Liu Shuang 愛媛大学, 医学系研究科, 講師 (60403812)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | カルシウムチャネル阻害剤 / 免疫抑制剤 / 関節リウマチ / 抗体製剤 / 核酸製剤 / Short-hairpin RNA / CARCチャネル阻害薬 / ヒト型関節リウマチモデル / SCIDマウス / 薬理効果 / 臨床研究 |
Outline of Final Research Achievements |
In this study, the inhibitors of calcium release-activated calcium channel (CRAC), including small molecular compound YM-58483, neutralizing antibody, and shor-harpin RNA, were used to investigate the feasibility in the treatment of rheumatoid arthritis (RA). The efficacy of CRAC inhibitors was demonstrated according to the results of this study. The CRAC inhibitors are expected as a group of new globle immunosuppressants.
|
Report
(4 results)
Research Products
(17 results)